Therapy with oncolytic viruses: progress and challenges.
Sophia Z Shalhout, David M Miller, Kevin S Emerick...
https://pubmed.ncbi.nlm.nih.gov/36631681/Actively Recruiting
Led by Jie Yuan,MD · Updated on 2026-09-30
30
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety, feasibility, and early antitumor activity of a combination treatment using an intratumoral oncolytic virus H101 and immune checkpoint inhibitors ICIs in patients with advanced metastatic colorectal cancer, gastric cancer, or hepatocellular carcinoma who have not responded to multiple prior therapies. This single-arm, open-label study also aims to explore how this combination changes the tumors immune environment and to identify potential biomarkers predicting treatment response. Participants receive intratumoral injections of H101 once every 2-3 weeks for four cycles, with the dose based on tumor size. Five to seven days after each H101 injection, they are given intravenous ICIs, either anti-PD-1 alone or combined with anti-CTLA-4 antibodies, according to the physicians choice. Tumor biopsies and blood samples are collected before starting treatment and after the final cycle to analyze immune changes and biomarkers. During the study, participants undergo regular clinical assessments, tumor imaging to evaluate response, and safety monitoring for adverse events. Adverse events are graded using standard criteria from the first dose until 30 days after treatment ends. Tumor responses are measured by established criteria, and progression-free survival is tracked for up to two years. All data are securely managed, and the study follows ethical guidelines with informed consent from all patients.
CONDITIONS
A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for Metastatic Tumors (Colorectal Cancer, Gastric Cancer, and Hepatocellular Carcinoma)
J
Jie Yuan, Doctoral degree
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jie Yuan,MD
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 to 12 weeks
Participants receive intratumoral injections of the oncolytic virus followed by intravenous immune checkpoint inhibitors every 2 to 3 weeks for four cycles.
4 treatment cycles with visits every 2 to 3 weeks
Duration - Up to 2 years
Participants undergo tumor imaging, safety monitoring, and biomarker analyses after treatment completion to evaluate response and immune changes.
Periodic assessments for progression-free survival and safety
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sophia Z Shalhout, David M Miller, Kevin S Emerick...
https://pubmed.ncbi.nlm.nih.gov/36631681/Charlotte Lovatt, Alan L Parker
https://pubmed.ncbi.nlm.nih.gov/37627206/Ramya Reddy, Sandra C Yan, Zahra Hasanpour Segherlou...
https://pubmed.ncbi.nlm.nih.gov/37877961/Zhijian Huang, Hongen Guo, Lin Lin...
https://pubmed.ncbi.nlm.nih.gov/37185868/Danni Lin, Yinan Shen, Tingbo Liang
https://pubmed.ncbi.nlm.nih.gov/37041165/Jie Yuan,MD
Lead Sponsor